• Ajinomoto, Bright Peak Enter Immunocytokines Research Pact contractpharma
    March 31, 2021
    ​Ajinomoto Bio-Pharma Services, a biopharmaceutical CDMO, and Bright Peak Therapeutics Inc., a biotechnology company developing next gen immunotherapies for cancer and autoimmune disease, have entered a research collaboration and exclusive license ...
PharmaSources Customer Service